Bisphosphonates, currently a first-line anti-osteoporosis drug, has been proven to have significant efficacy in reducing vertebral and non-vertebral fractures. However, studies in recent years have found that its long-term use is unable to produce additional benefits but rather may induce such serious adverse reactions as osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF), hence the concept of a “drug holiday”. This article reviews the literature of the “drug holiday” published both at home and abroad in recent years with a view to providing reference for more reasonable medication for the patients with primary osteoporosis.